These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 39034384)

  • 1. "Expected to happen": perspectives on post-release overdose from recently incarcerated people with opioid use disorder.
    Michener PS; Bianchet E; Fox S; Evans EA; Friedmann PD
    Harm Reduct J; 2024 Jul; 21(1):138. PubMed ID: 39034384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expanding access to Medication for Opioid Use Disorder (MOUD) in jails: A comprehensive program evaluation.
    Pourtaher E; Gelberg KH; Fallico M; Ellendon N; Li S
    J Subst Use Addict Treat; 2024 Jun; 161():209248. PubMed ID: 38081540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of jail-based methadone or buprenorphine treatment on non-fatal opioid overdose after incarceration.
    Cherian T; Lim S; Katyal M; Goldfeld KS; McDonald R; Wiewel E; Khan M; Krawczyk N; Braunstein S; Murphy SM; Jalali A; Jeng PJ; Rosner Z; MacDonald R; Lee JD
    Drug Alcohol Depend; 2024 Jun; 259():111274. PubMed ID: 38643529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Jail-based reentry programming to support continued treatment with medications for opioid use disorder: Qualitative perspectives and experiences among jail staff in Massachusetts.
    Matsumoto A; Santelices C; Evans EA; Pivovarova E; Stopka TJ; Ferguson WJ; Friedmann PD
    Int J Drug Policy; 2022 Nov; 109():103823. PubMed ID: 35994938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medication for opioid use disorder treatment continuity post-release from jail: A qualitative study with community-based treatment providers.
    Stopka TJ; Rottapel RE; Ferguson WJ; Pivovarova E; Toro-Mejias LD; Friedmann PD; Evans EA
    Int J Drug Policy; 2022 Dec; 110():103803. PubMed ID: 35965159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between jail-based methadone or buprenorphine treatment for opioid use disorder and overdose mortality after release from New York City jails 2011-17.
    Lim S; Cherian T; Katyal M; Goldfeld KS; McDonald R; Wiewel E; Khan M; Krawczyk N; Braunstein S; Murphy SM; Jalali A; Jeng PJ; MacDonald R; Lee JD
    Addiction; 2023 Mar; 118(3):459-467. PubMed ID: 36305669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medications for opioid use disorder in state prisons: Perspectives of formerly incarcerated persons.
    Treitler PC; Enich M; Reeves D; Crystal S
    Subst Abus; 2022; 43(1):964-971. PubMed ID: 35420973
    [No Abstract]   [Full Text] [Related]  

  • 8. Opioid-related treatment, interventions, and outcomes among incarcerated persons: A systematic review.
    Malta M; Varatharajan T; Russell C; Pang M; Bonato S; Fischer B
    PLoS Med; 2019 Dec; 16(12):e1003002. PubMed ID: 31891578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimated Costs and Outcomes Associated With Use and Nonuse of Medications for Opioid Use Disorder During Incarceration and at Release in Massachusetts.
    Chatterjee A; Weitz M; Savinkina A; Macmadu A; Madushani RWMA; Potee RA; Ryan D; Murphy SM; Walley AY; Linas BP
    JAMA Netw Open; 2023 Apr; 6(4):e237036. PubMed ID: 37058306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Massachusetts Justice Community Opioid Innovation Network (MassJCOIN).
    Evans EA; Stopka TJ; Pivovarova E; Murphy SM; Taxman FS; Ferguson WJ; Bernson D; Santelices C; McCollister KE; Hoskinson R; Lincoln T; Friedmann PD;
    J Subst Abuse Treat; 2021 Sep; 128():108275. PubMed ID: 33483222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing provision of MOUD and obstetric care in U.S. jails: A content analysis of policies submitted by 59 jails.
    Kao L; Lee C; Parayil T; Kramer C; Sufrin CB
    Drug Alcohol Depend; 2023 Jul; 248():109877. PubMed ID: 37244223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Transitions Clinic Network: Post Incarceration Addiction Treatment, Healthcare, and Social Support (TCN-PATHS): A hybrid type-1 effectiveness trial of enhanced primary care to improve opioid use disorder treatment outcomes following release from jail.
    Howell BA; Puglisi L; Clark K; Albizu-Garcia C; Ashkin E; Booth T; Brinkley-Rubinstein L; Fiellin DA; Fox AD; Maurer KF; Lin HJ; McCollister K; Murphy S; Morse DS; Shavit S; Wang K; Winkelman T; Wang EA
    J Subst Abuse Treat; 2021 Sep; 128():108315. PubMed ID: 33583610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. "Just fighting for my life to stay alive": a qualitative investigation of barriers and facilitators to community re-entry among people with opioid use disorder and incarceration histories.
    Hoffman KA; Thompson E; Gaeta Gazzola M; Oberleitner LMS; Eller A; Madden LM; Marcus R; Oberleitner DE; Beitel M; Barry DT
    Addict Sci Clin Pract; 2023 Mar; 18(1):16. PubMed ID: 36944998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of the implementation of medication for opioid use disorder and COVID-19 in a statewide correctional system on treatment engagement, postrelease continuation of care, and overdose.
    Klemperer EM; Wreschnig L; Crocker A; King-Mohr J; Ramniceanu A; Brooklyn JR; Peck KR; Rawson RA; Evans EA
    J Subst Use Addict Treat; 2023 Sep; 152():209103. PubMed ID: 37311520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Access to treatment for pregnant incarcerated people with opioid use disorder: Perspectives from community opioid treatment providers.
    King Z; Kramer C; Latkin C; Sufrin C
    J Subst Abuse Treat; 2021 Jul; 126():108338. PubMed ID: 34116823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Availability of Medications for the Treatment of Opioid Use Disorder Among Pregnant and Postpartum Individuals in US Jails.
    Sufrin C; Kramer CT; Terplan M; Fiscella K; Olson S; Voegtline K; Latkin C
    JAMA Netw Open; 2022 Jan; 5(1):e2144369. PubMed ID: 35050354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. United States county jail treatment and care of pregnant incarcerated persons with opioid use disorder.
    Benck KN; Seide K; Jones AK; Omori M; Rubinstein LB; Beckwith C; Nowotny KM
    Drug Alcohol Depend; 2023 Jun; 247():109863. PubMed ID: 37071946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A conceptual model for understanding post-release opioid-related overdose risk.
    Joudrey PJ; Khan MR; Wang EA; Scheidell JD; Edelman EJ; McInnes DK; Fox AD
    Addict Sci Clin Pract; 2019 Apr; 14(1):17. PubMed ID: 30982468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transitions of care between jail-based medications for opioid use disorder and ongoing treatment in the community: A retrospective cohort study.
    Krawczyk N; Lim S; Cherian T; Goldfeld KS; Katyal M; Rivera BD; McDonald R; Khan M; Wiewel E; Braunstein S; Murphy SM; Jalali A; Jeng PJ; Kutscher E; Khatri UG; Rosner Z; Vail WL; MacDonald R; Lee JD
    Drug Alcohol Depend; 2024 Aug; 261():111377. PubMed ID: 38924958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mobile addiction treatment and harm reduction services as tools to address health inequities: a community case study of the Brockton Neighborhood Health Center mobile unit.
    Pinkhover A; Celata K; Baker T; Chatterjee A; Lunze K
    Front Public Health; 2024; 12():1407522. PubMed ID: 38957203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.